127
Participants
Start Date
August 9, 2005
Primary Completion Date
May 4, 2017
Study Completion Date
May 4, 2017
Temozolomide
Focal RT 6000 cGy/ Temozolomide 75 mg/m2 then Temozolomide 50mg/m2 will be given to patients on days 1-28 of each 28 day cycle. Maintenance cis-retinoic acid. This therapy will start at the completion of 6 cycles of adjuvant temozolomide in all patients who have had no clinical or radiographic evidence of tumor progression.Treatment will continue in 28 day cycles until tumor progression.
Temozolomide
Focal RT 6000 cGy/ Temozolomide 75 mg/m2 plus Temozolomide 150 mg/m2 will be given to patients on days 1-7 and 15-21 of each 28 day cycle. Maintenance cis-retinoic acid. This therapy will start at the completion of 6 cycles of adjuvant temozolomide in all patients who have had no clinical or radiographic evidence of tumor progression.Treatment will continue in 28 day cycles until tumor progression.
Memorial Sloan-Kettering Cancer Center, New York
Memorial Sloan-Kettering Cancer Center at Commack, Commack
Memorial Sloan-Kettering at Basking Ridge, Basking Ridge
Collaborators (1)
Schering-Plough
INDUSTRY
Columbia University
OTHER
Dana-Farber Cancer Institute
OTHER
Memorial Sloan Kettering Cancer Center
OTHER